MELITAC 12.1 + Montanide ISA-51 + polyICLC

MELITAC 12.1 + Montanide ISA-51 + polyICLC is a combination immunotherapeutic regimen used primarily in clinical trials for melanoma. MELITAC 12.1 is a multipeptide vaccine composed of twelve Class I MHC-restricted melanoma peptides and a tetanus helper peptide, designed to elicit robust T-cell responses against melanoma antigens[7]. Montanide ISA-51 is an oil-based adjuvant similar to incomplete Freund’s adjuvant, enhancing immune response by creating a depot effect and stimulating local inflammation at the injection site[6][8][1]. PolyICLC (Hiltonol) is a synthetic double-stranded RNA that acts as an agonist for toll-like receptor 3 (TLR3), further boosting innate and adaptive immunity by mimicking viral infection signals[6][7]. This combination aims to maximize anti-tumor immune responses through synergistic activation of both innate and adaptive arms of the immune system, with demonstrated safety and immunogenicity in early-phase clinical studies for high-risk or advanced melanoma[2][6][7].

Other names

Incomplete Freund's adjuvant (for Montanide ISA-51)Hiltonol (for polyICLC)